Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 5/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7899220 | 0.86 | KMT2A (0.57) | KMT2APOLBMEN1MAPTALDH1A1 | |
| SCHEMBL6960427 | 0.84 | KMT2A (0.58) | KMT2APOLBMEN1MAPTALDH1A1 | |
| SCHEMBL17786550 | 0.82 | CSNK2A2 (0.55) | KMT2APOLBMEN1MAPTALDH1A1 | |
| SCHEMBL5564057 | 0.82 | ALDH1A1 (0.55) | KMT2APOLBMEN1MAPTALDH1A1 | |
| SCHEMBL7834019 | 0.81 | PIM1 (0.55) | KMT2APOLBMEN1MAPTALDH1A1 | |
| SCHEMBL13855906 | 0.81 | ALDH1A1 (0.63) | POLBMAPTALDH1A1KDM4ECSNK2A2 | |
| SCHEMBL5564194 | 0.81 | ALDH1A1 (0.56) | KMT2APOLBMEN1ALDH1A1KDM4E | |
| SCHEMBL17786530 | 0.80 | CSNK2A2 (0.65) | KMT2APOLBMEN1MAPTALDH1A1 | |
| SCHEMBL17786578 | 0.79 | CSNK2A2 (0.64) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL6961369 | 0.78 | CSNK2A2 (0.51) | KMT2APOLBMEN1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603912-B1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-07-18 | — | — | EP | disclosed |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-07-05 | — | — | US | disclosed |
| US-20070037823-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20060276485-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-12-07 | — | — | US | disclosed |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-10-26 | — | — | US | disclosed |
| EP-1606278-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-21 | — | — | EP | disclosed |
| EP-1606281-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-21 | — | — | EP | disclosed |
| EP-1603912-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| EP-1603911-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083199-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083208-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083209-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083198-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037823-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | KMT2A 699/4885POLB 2960/4885MEN1 1836/4885 |
| US-20060276485-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | KMT2A 679/4885POLB 2972/4885MEN1 1857/4885 |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | KMT2A 924/4885POLB 3261/4885MEN1 1874/4885 |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | KMT2A 679/4885POLB 2972/4885MEN1 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.